Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL309998 | 0.99 | ACACB (0.99) | ACACBACACA | |
| SCHEMBL310000 | 0.99 | ACACB (0.99) | ACACBACACA | |
| SCHEMBL308274 | 0.95 | ACACB (0.90) | ACACBACACA | |
| SCHEMBL309999 | 0.94 | ACACB (0.89) | ACACBACACA | |
| SCHEMBL10252528 | 0.93 | ACACB (0.87) | ACACBACACA | |
| SCHEMBL309737 | 0.93 | ACACB (0.86) | ACACBACACA | |
| SCHEMBL308818 | 0.93 | ACACB (0.86) | ACACBACACA | |
| SCHEMBL308816 | 0.93 | ACACB (0.86) | ACACBACACA | |
| SCHEMBL308838 | 0.93 | ACACB (0.86) | ACACBACACA | |
| SCHEMBL308841 | 0.92 | ACACB (0.85) | ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 287 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177367-A1 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION | 2025-06-05 | — | — | US | claimed |
| CN-119677539-A | Combination therapy for modulating lipid production | 俄亥俄州创新基金会 | 2025-03-21 | — | — | CN | claimed |
| EP-4489865-A2 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | Ohio State Innovation Foundation (US) | 2025-01-15 | — | — | EP | claimed |
| CN-118717997-A | Pharmaceutical composition containing acetyl-CoA carboxylase inhibitor and application thereof | 深圳奥萨制药有限公司 | 2024-10-01 | — | — | CN | claimed |
| WO-2024192080-A1 | METHODS OF TREATING, PREVENTING, AND/OR AMELIORATING CANCER WITH ACETYL COENZYME A (COA) CARBOXYLASE INHIBITOR(S) | YALE UNIVERSITY (US) | 2024-09-19 | — | — | WO | claimed |
| WO-2023172669-A9 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION (US) | 2024-08-02 | — | — | WO | claimed |
| WO-2023172669-A2 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-14 | — | — | WO | claimed |
| US-20230256051-A1 | MODIFIED KISSPEPTIN RECEPTOR AGONISTS FOR FATTY LIVER DISEASE | UNIV RUTGERS (US) | 2023-08-17 | — | — | US | claimed |
| US-20230084144-A1 | THERAPEUTIC COMBINATIONS OF DRUGS AND METHODS OF USING THEM | CONSYNANCE THERAPEUTICS INC (US) | 2023-03-16 | — | — | US | claimed |
| EP-4132559-A1 | MODIFIED KISSPEPTIN RECEPTOR AGONISTS FOR FATTY LIVER DISEASE | Rutgers, the State University of New Jersey (US) | 2023-02-15 | — | — | EP | claimed |
| CN-115590966-A | Therapeutic combinations of drugs and methods of use thereof | 康圣博施医药有限公司（US） | 2023-01-13 | — | — | CN | claimed |
| CN-115350184-A | Therapeutic combinations of drugs and methods of use thereof | 康圣博施医药有限公司 | 2022-11-18 | — | — | CN | claimed |
| US-20220347190-A1 | TREATMENT COMPRISING FXR AGONISTS | NOVARTIS AG (CH) | 2022-11-03 | — | — | US | claimed |
| US-11484517-B2 | Combination comprising a PPAR agonist such as elafibranor and an acetyl-CoA carboxylase (ACC) inhibitor | GENFIT (FR) | 2022-11-01 | — | — | US | claimed |
| EP-4076527-A1 | THERAPEUTIC COMBINATIONS OF DRUGS AND METHODS OF USING THEM | Consynance Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | claimed |
| EP-4031137-A1 | TREATMENT COMPRISING FXR AGONISTS | Novartis AG (CH) | 2022-07-27 | — | — | EP | claimed |
| CN-114401745-A | Treatment comprising FXR agonists | 诺华股份有限公司 | 2022-04-26 | — | — | CN | claimed |
| EP-2111406-B1 | SUBSTITUTED SPIROCHROMANONE DERIVATIVES AS ACC INHIBITORS | MERCK SHARP & DOHME (US) | 2012-10-24 | — | — | EP | claimed |
| US-8093389-B2 | e.g. 1-[(1-Ethyl-4-methoxy-1H-benzimidazol-6-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4'-piperidine]-4-one; acetyl CoA carboxylase inhibitors; antidiabetic, hypoglycemic agent; metabolic syndrome, fatty liver, hyperlipemia, obesity, diabetes, bulimia, malignant neoplasm or infectious diseases | MERCK SHARP & DOHME CORP. (US) | 2012-01-10 | — | — | US | claimed |
| US-20080171761-A1 | Substituted spirochromanone derivatives | MERCK SHARP & DOHME LLC | 2008-07-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230084144-A1 | THERAPEUTIC COMBINATIONS OF DRUGS AND METHODS OF USING THEM | MCHR1, MCHR2, MC1R | ACACB 3883/4885ACACA 3331/4885 |
| US-20220347190-A1 | TREATMENT COMPRISING FXR AGONISTS | NR1H4, FXR1, FXR2 | ACACB 334/4885ACACA 173/4885 |
| US-20250177367-A1 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | ACACB, SREBF2, FASN | ACACB 1/4885ACACA 5/4885 |
| US-20230256051-A1 | MODIFIED KISSPEPTIN RECEPTOR AGONISTS FOR FATTY LIVER DISEASE | KISS1R, GLP1R, GPR119 | ACACB 1631/4885ACACA 1138/4885 |
| US-11484517-B2 | Combination comprising a PPAR agonist such as elafibranor and an acetyl-CoA carboxylase (ACC) inhibitor | ACACA, PPARA, PPARG | ACACB 4/4885ACACA 1/4885 |
| US-20080171761-A1 | Substituted spirochromanone derivatives | CBR3, CBR1, CNKSR1 | ACACB 713/4885ACACA 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.